Jazz Pharmaceuticals (JAZZ) Hits New 52-Week High and Low at $168.64

Jazz Pharmaceuticals (NASDAQ:JAZZ)’s share price hit a new 52-week high and low during trading on Monday . The company traded as low as $168.64 and last traded at $166.36, with a volume of 8885 shares trading hands. The stock had previously closed at $166.96.

JAZZ has been the topic of a number of research reports. Morgan Stanley raised shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $128.58 to $163.75 in a research note on Monday, March 19th. Bank of America raised their target price on shares of Jazz Pharmaceuticals from $164.00 to $170.00 and gave the company a “buy” rating in a research note on Tuesday, February 20th. BidaskClub raised shares of Jazz Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Tuesday, March 13th. Piper Jaffray Companies reissued a “buy” rating and issued a $201.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday, March 1st. Finally, HC Wainwright reissued a “neutral” rating and issued a $160.00 target price (up previously from $150.00) on shares of Jazz Pharmaceuticals in a research note on Friday, March 23rd. Six analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. Jazz Pharmaceuticals presently has an average rating of “Buy” and an average target price of $181.86.

The firm has a market cap of $9.96 billion, a price-to-earnings ratio of 17.38, a price-to-earnings-growth ratio of 0.85 and a beta of 0.97. The company has a current ratio of 3.00, a quick ratio of 2.88 and a debt-to-equity ratio of 0.55.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings results on Tuesday, February 27th. The specialty pharmaceutical company reported $2.58 earnings per share for the quarter, missing the Zacks’ consensus estimate of $2.73 by ($0.15). The firm had revenue of $436.40 million for the quarter, compared to analyst estimates of $440.91 million. Jazz Pharmaceuticals had a net margin of 26.51% and a return on equity of 23.78%. research analysts predict that Jazz Pharmaceuticals will post 11.65 EPS for the current year.

In other Jazz Pharmaceuticals news, SVP Paul Treacy sold 877 shares of the firm’s stock in a transaction on Friday, March 2nd. The shares were sold at an average price of $139.62, for a total transaction of $122,446.74. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Karen J. Wilson sold 3,899 shares of the firm’s stock in a transaction on Tuesday, April 10th. The stock was sold at an average price of $155.00, for a total transaction of $604,345.00. Following the transaction, the senior vice president now directly owns 19,517 shares of the company’s stock, valued at $3,025,135. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 20,837 shares of company stock valued at $3,200,686. Company insiders own 4.30% of the company’s stock.

Hedge funds have recently made changes to their positions in the business. US Bancorp DE grew its holdings in Jazz Pharmaceuticals by 49.5% during the 4th quarter. US Bancorp DE now owns 1,087 shares of the specialty pharmaceutical company’s stock worth $147,000 after acquiring an additional 360 shares in the last quarter. We Are One Seven LLC acquired a new position in Jazz Pharmaceuticals during the 4th quarter worth $157,000. Financial Gravity Companies Inc. grew its holdings in Jazz Pharmaceuticals by 124.6% during the 1st quarter. Financial Gravity Companies Inc. now owns 1,271 shares of the specialty pharmaceutical company’s stock worth $192,000 after acquiring an additional 705 shares in the last quarter. Brighton Jones LLC acquired a new position in Jazz Pharmaceuticals during the 1st quarter worth $205,000. Finally, Invictus RG acquired a new position in Jazz Pharmaceuticals during the 4th quarter worth $206,000. 89.23% of the stock is owned by institutional investors.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply